Burkitt's lymphoma overview

Jump to navigation Jump to search

Burkitt's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings

CT

MRI

Biopsy

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Burkitt's lymphoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma overview

CDC on Burkitt's lymphoma overview

Burkitt's lymphoma overview in the news

Blogs on Burkitt's lymphoma overview

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Burkitt's lymphoma (or "Burkitt's tumor", or "Malignant lymphoma, Burkitt's type") is a cancer of the lymphatic system (in particular, B lymphocytes). It is associated with the Epstein-Barr virus, also the cause of mononucleosis as well as other cancers. It is named after Denis Parsons Burkitt, a surgeon who first described the disease in 1956 while working in equatorial Africa.

Children affected with the disease often also had chronic malaria which is believed to have reduced resistance to the Epstein-Barr virus and allowed it to take hold. This is known as classical African or endemic Burkitt's lymphoma. Disease characteristics include large tumors in the facial or abdominal regions.

The sporadic type of Burkitt's lymphoma (also known as "non-African") is another form of non-Hodgkin lymphoma found outside of Africa in which cancer cells have a similar appearance to the cancer cells of classical African or endemic Burkitt's lymphoma. Again it is believed that impaired immunity provides an opening for development of the Epstein-Barr virus. Examination of chromosomes from these tumor cells often shows translocation of the myc and Ig genes (t: 8;14).

Historical Perspective

Burkitt's lymphoma was first described by Denis Parsons Burkitt, a surgeon, in 1958 while working in equatorial Africa.

Classification

Burkitt's lymphoma may be classified according to WHO classification into 3 clinical variants: endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, and immunodeficiency-associated Burkitt's lymphoma.

Pathophysiology

Gene involved in the pathogenesis of Burkitt's lymphoma includes c-myc. On gross pathology, ulceration and discharge are characteristic findings of Burkitt's lymphoma. On microscopic histopathological analysis, "starry sky" appearance is characteristic finding of Burkitt's lymphoma.

Causes

There are no established causes for Burkitt's lymphoma.

Differential diagnosis

Burkitt's lymphoma must be differentiated from other diseases such as Hodgkin's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, Mucosa-Associated Lymphatic Tissue lymphoma (MALT), small cell lymphocytic lymphoma, and mantle cell lymphoma (MCL).

Epidemiology and Demographics

Burkitt's lymphoma is a common disease that tends to affect children or young adults. Males are more commonly affected with Burkitt's lymphoma than females. Burkitt's lymphoma usually affects individuals of the African race.

Risk Factors

Common risk factors in the development of Burkitt's lymphoma may be HIV/AIDS and post-transplant immunosuppression.

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for Burkitt's lymphoma.

Prognosis

The prognosis varies with the age, children have the most favorable prognosis. Burkitt's lymphoma in children is associated with a 5 year survival rate of 90%. The presence of metastasis in bone marrow or CNS is associated with a particularly poor prognosis among patients with Burkitt's lymphoma.

Diagnosis

Staging

According to the Murphy staging system, there are four stages of Burkitt's lymphoma based on the number of nodes and extra nodal involvement.

Laboratory Findings

Laboratory tests for Burkitt's lymphoma include complete blood count (CBC), blood chemistry studies, immuno histochemistry, HIV blood test, flow cytometric analysis, and cytogenetics.

X Ray Findings

Chest and knee x ray may be helpful in the diagnosis of Burkitt's lymphoma.

CT

Chest, abdomen, and pelvis CT scan may be helpful in the diagnosis of Burkitt's lymphoma.

MRI

MRI scan may be helpful in the diagnosis of Burkitt's lymphoma.

Biopsy

Lymph node or extra nodal tissue biopsy is diagnostic of Burkitt's lymphoma.

Other Imaging Studies

PET scan and bone scan may be helpful in the diagnosis of Burkitt's lymphoma.

Other diagnostic studies

Other diagnostic studies for the diagnosis of Burkitt's lymphoma include bone marrow biopsy and spinal fluid examination.

Treatment

Medical Therapy

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.

Surgery

Surgical intervention is not recommended for the management of Burkitt's lymphoma.

References

Template:Chromosomal abnormalities


Template:WikiDoc Sources